CareDx helps biopharmaceutical companies run large, multicenter clinical trials. With AlloCell offering highly sensitive NGS surveillance for allogeneic cell therapy, CareDx can guide clinical decisions through precise measurements. This next-generation sequencing and surveillance tool measures the amount of allogeneic cell product relative to a patient’s target with the aim to:

  • Accelerate development and shorten clinical trials to drive faster therapy outcomes
  • Create resourcing and cost savings by requiring significantly less lab personnel and less DNA input
  • Establish potential usage of AlloCell results as secondary endpoint in registrational trials
  • Produce outcomes using this noninvasive technique that are shown to be similar to invasive biopsies in clinical study